Insider Selling: Doximity, Inc. (NASDAQ:DOCS) Insider Sells 1,000 Shares of Stock

Doximity, Inc. (NASDAQ:DOCSGet Free Report) insider Craig Overpeck sold 1,000 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $21.48, for a total value of $21,480.00. Following the completion of the sale, the insider now owns 120,741 shares in the company, valued at approximately $2,593,516.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Doximity Stock Down 1.7 %

Shares of NASDAQ DOCS traded down $0.36 during midday trading on Tuesday, reaching $20.40. The company had a trading volume of 3,091,504 shares, compared to its average volume of 1,935,065. The stock has a market cap of $3.97 billion, a PE ratio of 36.59, a price-to-earnings-growth ratio of 4.86 and a beta of 1.02. Doximity, Inc. has a one year low of $20.34 and a one year high of $40.12. The firm’s fifty day moving average price is $27.95 and its 200-day moving average price is $31.13.

Doximity (NASDAQ:DOCSGet Free Report) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. Doximity had a return on equity of 13.11% and a net margin of 27.20%. The business had revenue of $108.47 million for the quarter, compared to analysts’ expectations of $106.98 million. As a group, equities research analysts expect that Doximity, Inc. will post 0.61 EPS for the current year.

Institutional Investors Weigh In On Doximity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. purchased a new position in shares of Doximity in the second quarter valued at about $27,000. Quarry LP bought a new position in Doximity during the 1st quarter valued at approximately $38,000. American International Group Inc. bought a new stake in shares of Doximity in the 2nd quarter worth approximately $43,000. Neo Ivy Capital Management increased its stake in shares of Doximity by 12,750.0% during the fourth quarter. Neo Ivy Capital Management now owns 1,542 shares of the company’s stock valued at $52,000 after buying an additional 1,530 shares during the period. Finally, OLD Mission Capital LLC bought a new position in shares of Doximity during the fourth quarter valued at approximately $56,000. 54.65% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Raymond James dropped their price target on Doximity from $40.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, August 9th. Piper Sandler decreased their price target on shares of Doximity from $36.00 to $27.00 in a report on Wednesday, August 9th. Wells Fargo & Company dropped their price objective on shares of Doximity from $37.00 to $25.00 and set an “equal weight” rating for the company in a report on Thursday, August 10th. Needham & Company LLC cut Doximity from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Bank of America dropped their price target on Doximity from $28.00 to $24.00 in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. Based on data from, the stock currently has a consensus rating of “Hold” and a consensus target price of $29.50.

Get Our Latest Analysis on DOCS

Doximity Company Profile

(Get Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Recommended Stories

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with's FREE daily email newsletter.